MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Bayer AG

Abrir

SetorFinanças

21.795 1.87

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.405

Máximo

21.835

Indicadores-chave

By Trading Economics

Rendimento

3.9B

-328M

Vendas

1.8B

12B

P/E

Médio do Setor

30.9

22.015

EPS

1.05

Rendimento de Dividendos

0.49

Margem de lucro

-2.796

Funcionários

90,587

EBITDA

615M

1.7B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+20.47% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.49%

3.90%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

422M

22B

Abertura anterior

19.93

Fecho anterior

21.795

Sentimento de Notícias

By Acuity

26%

74%

87 / 542 Ranking em Finance

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Bayer AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de mar. de 2025, 09:37 UTC

Grandes Movimentos do Mercado

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 de mar. de 2025, 11:21 UTC

Ganhos

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5 de mar. de 2025, 08:45 UTC

Ganhos

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5 de mar. de 2025, 07:26 UTC

Ganhos

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2 de abr. de 2025, 09:27 UTC

Ações em Alta

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 de mar. de 2025, 08:38 UTC

Conversa de Mercado

Bayer's Partial Recovery Is in Sight -- Market Talk

5 de mar. de 2025, 13:39 UTC

Conversa de Mercado
Ganhos

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5 de mar. de 2025, 13:26 UTC

Conversa de Mercado

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5 de mar. de 2025, 08:30 UTC

Conversa de Mercado
Ganhos

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5 de mar. de 2025, 06:41 UTC

Ganhos

Bayer Launches Plan to Boost Profitability at Crop Science

5 de mar. de 2025, 06:40 UTC

Ganhos

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5 de mar. de 2025, 06:39 UTC

Ganhos

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5 de mar. de 2025, 06:39 UTC

Ganhos

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5 de mar. de 2025, 06:36 UTC

Ganhos

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5 de mar. de 2025, 06:35 UTC

Ganhos

Bayer Guidance is on a Currency Adjusted Basis

5 de mar. de 2025, 06:34 UTC

Ganhos

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5 de mar. de 2025, 06:34 UTC

Ganhos

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5 de mar. de 2025, 06:33 UTC

Ganhos

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5 de mar. de 2025, 06:33 UTC

Ganhos

Bayer Sees 2025 Sales EUR45B-EUR47B

5 de mar. de 2025, 06:32 UTC

Ganhos

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5 de mar. de 2025, 06:31 UTC

Ganhos

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5 de mar. de 2025, 06:31 UTC

Ganhos

Bayer 4Q Net Loss EUR335M

5 de mar. de 2025, 06:31 UTC

Ganhos

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 de mar. de 2025, 06:31 UTC

Ganhos

Bayer 4Q Ebitda Before Special Items EUR2.35B

5 de mar. de 2025, 06:31 UTC

Ganhos

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5 de mar. de 2025, 06:31 UTC

Ganhos

Bayer 4Q Sales EUR11.73B

13 de jan. de 2025, 21:05 UTC

Principais Notícias

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 de jan. de 2025, 15:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Didn't Disclose Financial Details

9 de jan. de 2025, 15:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 de jan. de 2025, 15:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Camelina Is Novel Intermediate Oilseed Crop

Comparação entre Pares

Variação de preço

Bayer AG Previsão

Preço-alvo

By TipRanks

20.47% parte superior

Previsão para 12 meses

Média 26.89 EUR  20.47%

Máximo 33 EUR

Mínimo 22 EUR

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Bayer AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

10 ratings

1

Comprar

9

Manter

0

Vender

Pontuação Técnica

By Trading Central

21.95 / 22.575Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

87 / 542 Ranking em Finanças

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.